STOCK TITAN

Eikon Therapeutics (EIKN) Stock Price, News & Analysis

EIKN NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
71 196 sessions, February 5, 2026 to November 13, 2026
Largest daily move
-23.7% close of October 26, 2026
1-month change
-11% closing prices, October 13, 2026 to November 13, 2026

Company Description

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company developing medicines for serious unmet medical needs. The company operates as a drug discovery and clinical development business and reports a single operating segment focused on product candidates discovered or advanced through its proprietary technology platform. Its common stock trades on the Nasdaq Stock Market under the symbol EIKN.

Eikon’s pipeline includes multiple internally identified product candidates, including EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006. The company’s disclosed clinical work is concentrated in oncology. EIK1001 is being developed in non-small cell lung cancer, including first-line treatment of stage 4 disease. EIK1003 is being evaluated in cancer settings that include prostate cancer, breast cancer, and ovarian cancer, both as a monotherapy and in combination-based approaches. EIK1004 is a highly selective PARP1 inhibitor designed to cross the blood-brain barrier and is being studied in advanced solid tumors, including patients with active brain metastases.

The company’s business model is based on drug discovery, clinical development, and the potential advancement of product candidates through later-stage studies and regulatory pathways. As a clinical-stage biopharmaceutical issuer, Eikon’s operating disclosures center on research and development activity, clinical program progress, corporate financing, governance, and capital structure rather than commercial product sales.

Eikon is headquartered in Millbrae, California. The company completed its initial public offering in February 2026 and became a Nasdaq-listed public company with common stock registered under Section 12(b) of the Securities Exchange Act of 1934.

Stock Performance

$5.98
-0.99%
-0.06
Last updated: November 13, 2026 at 16:00
-11%
Performance 1 month
$324.0M

Eikon Therapeutics (EIKN) closed at $5.98 on November 13, 2026. Over the past month, the price has lost 11.0%.

See what a $1,000 investment in EIKN would be worth today

Average down calculator for EIKN

EIKN Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Eikon Therapeutics has 10 recent news articles, with the latest published 3 days ago. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, conferences. View all EIKN news →

Insider Radar

Net Buyers
90-Day Summary
89,200
Shares Bought
0
Shares Sold
1
Transactions
Most Recent Transaction
Column Group IV-A, LP (10% Owner) bought 89,200 shares held indirectly @ $11.56 on September 3, 2026

Insider buying activity at Eikon Therapeutics over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Eikon Therapeutics has not filed a full fiscal year of results yet, so there are no annual figures to show here, and the quarterly figures it has reported so far are on its financials page.

Upcoming Events

YEAR
2027
2027 Clinical

Program data release

Eikon expects additional 2027 clinical results across programs, including EIK1003 and EIK1004 combination data; timing within 2027.
H2
2027
H2 2027 Clinical

Dose-selection interim analysis

Interim dose-selection analysis for TeLuRide-008 Phase 2/3 trial (EIK1001+pembrolizumab+chemotherapy); enrolling; timing H2 2027.
H2
2027
H2 2027 Financial

Cash runway into 2H 2027

Company expects cash to fund operations into the second half of 2027.
Q1
2028
Q1 2028 Financial

Funding runway end

Cash $461.7M at Sept 30; company expects funding to last into Q1 2028 (runway through Mar 31, 2028).

Eikon Therapeutics has 4 upcoming scheduled events. The next event, "Program data release", is expected in 2027. 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the EIKN stock price.

Short Interest History

Last 12 Months

Short interest in Eikon Therapeutics (EIKN) currently stands at 5.5 million shares, down 13.1% from the previous reporting period, representing 13.5% of the float. Since February 2026, short interest has increased by 537.7%.

Days to Cover History

Last 12 Months

Days to cover for Eikon Therapeutics (EIKN) currently stands at 10.5 days, down 10.4% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since February 2026, the figure has increased by 787.3%. Across the settlements charted above, it has ranged from 1.2 to 20.0 days.

EIKN Company Profile & Sector Positioning

Eikon Therapeutics (EIKN) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing EIKN often look at related companies in the same sector, including AgomAb Therapeutics NV (AGMB), Altimmune, Inc. (ALT), Evommune, Inc. (EVMN), Lyell Immunopharma, Inc. (LYEL), and Enanta Pharmaceuticals, Inc (ENTA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate EIKN's relative position within its industry.

Frequently Asked Questions

The current stock price of Eikon Therapeutics (EIKN) is $5.98 as of November 13, 2026.

The market cap of Eikon Therapeutics (EIKN) is approximately $324.0M. Learn more about what market capitalization means .

Eikon Therapeutics is a late-stage clinical biopharmaceutical company developing medicines for serious unmet medical needs through drug discovery and clinical development.

Eikon Therapeutics' common stock trades on the Nasdaq Stock Market under the symbol EIKN.

Eikon operates in a single operating segment focused on drug discovery using its proprietary technology and the clinical development of its product candidates.

Eikon's identified product candidates include EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

Eikon's disclosed clinical programs are concentrated in oncology, including non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, and advanced solid tumors.

EIK1004 is described by Eikon as a highly selective PARP1 inhibitor designed to cross the blood-brain barrier and evaluated in advanced solid tumors, including patients with active brain metastases.

Eikon Therapeutics is headquartered in Millbrae, California.